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Objective: To assess the efﬁcacy of thrice daily topical 4Jointz utilizing Acteev technology (a combination
of a standardized comfrey extract and a pharmaceutical grade tannic acid, 3.5 g/day) on osteoarthritic
knee pain, markers of inﬂammation and cartilage breakdown over 12 weeks.
Patients and methods: Adults aged 50e80 years (n ¼ 133) with clinical knee OA were randomised to
receive 4Jointz or placebo in addition to existing medications. Pain and function were measured using
a visual analogue scale (VAS) and the Knee Injury and Osteoarthritis Outcome Score (KOOS) scale at
baseline, 4, 8 and 12 weeks. Inﬂammation was measured analysing IL-6 expression and CTX-2 presence
as representative for cartilage breakdown using ELISA, at baseline and 12 weeks.
Results: Pain scores signiﬁcantly reduced in the group who received 4Jointz compared to the group who
received placebo after 12 weeks using both the VAS (9.9 mm, P ¼ 0.034) and the KOOS pain scale
(þ5.7, P ¼ 0.047). Changes in IL-6 and CTX-2 were not signiﬁcant (0.04, P ¼ 0.5; 0.01, P ¼ 0.68).
Post-hoc analyses suggested that treatment may be most effective in women (VAS 16.8 mm, P ¼ 0.008)
and those with milder radiographic osteoarthritis (OA) (VAS 16.1 mm, P ¼ 0.009). Rates of adverse
events were similar in both groups, excepting local rash that was more common amongst participants
receiving 4Jointz (21% vs 1.6%, IRR 13.2, P ¼ 0.013), but only 26% (n ¼ 4) of participants with rashes
discontinued treatment. There were no changes in systemic blood results.
Conclusions: Topical treatment using 4Jointz reduced pain but had no effect on inﬂammation or cartilage
breakdown over 12 weeks of treatment.
Trial registration: Australia and New Zealand Clinical Trials registry ACTRN12610000877088.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Knee osteoarthritis (OA) is common and is associated with pain
and disability. Management of OA involves symptom control,
usually non-steroidal anti-inﬂammatory medications (NSAIDs) or
analgesic medication. The controversy surrounding COX-2 inhibitorL. Laslett, Menzies Research







s Research Society International. Puse and heightened cardiovascular risk1e4, highlights the impor-
tance of ﬁnding safer treatment options to minimise adverse side
effects5. Natural agents such as capsaicin6, and vitamins5 have
demonstrated improved overall patient outcomes, and may play
a role in treatment of OA even if they are only moderately effective.
Comfrey (Symphytum ofﬁcinale) is traditionally used to treat
bone fractures, sprains and wounds7 as it demonstrates anti-
inﬂammatory and analgesic properties. A topical comfrey applica-
tion (vs placebo) on acute ankle sprains in 142 participants
decreased pain and swelling and improved mobility8.
There were no reported adverse reactions and sole therapy was
reported superior to a mixed comfrey and NSAID formulation9,10.
Comfrey has also been used to speciﬁcally treat OAwith two-thirds
of recipients reducing or discontinuing their NSAID treatment11.
Moreover, in a study involving 220 patients diagnosed with OA,ublished by Elsevier Ltd. All rights reserved.
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tion in VAS pain scores12.
Persons with OA have been reported to have high levels of free
radicals and reduced levels of antioxidants within the joint ﬂuid13.
Antioxidants such as tannic acid protect against the extracellular
matrix cartilage degradation that radicals yield14 and augment
glycosaminoglycan binding to collagen. This ultimately contributes
to the structural reinforcement of synovial articulating surfaces15.
Preparations of tannic acid have been found to be superior to
placebo in reducing pain and stiffness and improving physical
function in primary OA5.
Therefore, a number of complementary medicinal agents may be
effective in reducing pain and inﬂammation. A pilot study of treat-
ment using two different concentrations of comfrey vs placebo16
showed that the comfrey mixtures were both superior to placebo
in reducing WOMAC pain and stiffness scores, but there was no
difference in outcomes between different concentrations. Grube
et al.12 also compared a comfrey root extract with placebo for painful
kneeOA (averageduration6.5 years). Theyobserveda large reduction
in pain VAS score, andWOMAC scores between comfrey and placebo
after 3 weeks but this trial had methodological shortcomings.
We aimed to compare the effect of thrice daily topical 4Jointz
utilizing Acteev technology (a novel and patented combination of
a standardized comfrey extract and a pharmaceutical grade tannic
acid, 3.5 g/day), or placebo on osteoarthritic knee pain, muscle
strength, and markers of inﬂammation and cartilage breakdown
over 12 weeks in participants aged >50 with OA and a pain
intensity score >40 mm on a visual analogue scale (VAS).
Methods
Trial design
This study was a two centre double blind parallel-group placebo
controlled randomised trial of topical 4Jointz vs placebo with a 1:1
allocation ratio.
Settings and locations
Participants were recruited from September 2010 to May 2011
through advertising in local print media in Hobart, Tasmania and
Sydney, New SouthWales in Australia. Participants attended clinics
at either the Menzies Research Institute Tasmania in Hobart, or the
Royal North Shore Hospital in Sydney.
Inclusion and exclusion criteria
Participants were aged >50 years, with clinical knee OA
conﬁrmed by a Rheumatologist using American College of Rheu-
matology (ACR) criteria17, and had knee pain on most days
of>40mmon a 100mmVAS on their worst knee. Participants were
excluded if they had knee X-rays with Grade 3 joint space nar-
rowing (JSN) using the Osteoarthritis Research Society International
(OARSI) atlas18, read by chief investigators (GJ and LM) on diag-
nostic radiographs; had other forms of arthritis (including hip OA);
had signiﬁcant knee injury in the last 6 months; or were unable to
provide informed consent. Participants who were otherwise
eligible and had Grade 3 JSN in their worst knee were able to enter
the study if JSN was <3 in the other knee.
Participants
Participants were screened over the telephone. If they met the
inclusion criteria and did not meet the exclusion criteria, they were
invited to attend a study centre for screening. Screening andexamination was undertaken by a rheumatologist (GJ, LM) and
a nurse (MC, MG, TF). Participants supplied a blood specimen for
serum chemistry, renal function and inﬂammatory markers; a urine
sample for cartilage metabolites; and had a semi-ﬂexed knee X-ray.
Use of othermedication (including painmedicines) was allowed but
kept constant through the trial period where possible. All partici-
pants provided written consent. The study was approved by the
Human Research Ethics Committee (Tasmania) Network and the
Northern Sydney Local Health District Human Research Ethics
Committee and was performed in compliance with the Helsinki
Declaration.Interventions
Participants received either 4Jointz cream or identical but inert
placebo. This is a combination of a standardized comfrey extract
(200 mg/g) and pharmaceutical grade tannic acid (100 mg/g) plus
other ingredients including aloe vera gel (300 mg/g), eucalyptus oil
(40 mg/g), and frankincense oil (1.0 mg/g).
Participants were instructed to apply enough cream to coat the
knee with a thin coating which was then massaged in using gentle
circular motions for 3e5 min three times daily. Participants were
supplied one 100 g tube of cream at each visit. Therefore the daily
dose was approximately 3.5 g/day. Study medication was stored in
a locked cupboard prior to dispensing, and dispensed when
patients successfully completed the screening visit(s). Treatment
continued for 12 weeks, where medication use was discontinued
while maintaining the blind in order to observe response to treat-
ment withdrawal. Participants were re-assessed at 16 weeks.Outcomes
Primary hypotheses were that 4Jointz was superior to placebo at
12weeks for change in: knee pain [using the pain intensity VAS and
the pain scale from the Knee Injury and Osteoarthritis Outcome
Score (KOOS) Questionnaire]; markers of inﬂammation (IL-6), and
cartilage breakdown (CTX-2).
Secondary hypotheses were that 4Jointz was superior to placebo
for change in: pain between baseline and 4 and 8 weeks; response
using the Osteoarthritis Research Society International (OARSI)
response criteria19, lower limb muscle strength and use of para-
cetamol between baseline and 4, 8 and 12 weeks.
Additionally, we observed the effect of treatment withdrawal on
pain, KOOS scales, OARSI response criteria, muscle strength and
paracetamol use, by observing change in these outcomes between
cessation of treatment at 12 weeks and the last observations at 16
weeks. All hypotheses were a priori.Outcome measures
Pain and function
Knee pain intensity was measured using a 100 mm VAS on four
occasions (baseline, 4, 8, 12 and 16 weeks). Participants were asked
“on this line, where would you rate your pain today?”.
Knee pain and symptoms were also assessed using the KOOS
questionnaire on all ﬁve occasions20. These two subscales have nine
(pain) and seven (symptoms) questions, each with ﬁve response
levels scored from 0 to 4. Subscales were transformed according to
instructions in the original manuscript20. The transformed scale
had possible values from 0 to 100 with zero representing extreme
knee problems and 100 representing no knee problems. Baseline
questionnaires were completed in the clinic. Subsequent ques-
tionnaires were completed by mail.
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Urine and blood samples were collected at baseline and 12
weeks stored at 80C. Samples were assayed in duplicate for the
cartilage breakdown marker CTX-II (urine) using a Human CTX-2
Enzyme-linked immunosorbant assay (ELISA) kit (Cusabio Biotech
Co, Hubei Province, China), and for the inﬂammatory marker IL-6
(blood) using a Human IL-6 ELISA MAX Deluxe SET kit (Biolegend,
California, USA) following the manufacturers’ instructions. Urine
was diluted 1:2, and blood was used undiluted for the assay.
Absorbance was read at 450 nm with reference wavelength at
570 nm. Samples with <1 ng/mL (CTX) or <1 pg/mL (IL-6) were
deemed out of range and analysed with a value of zero.
A standard curve was run on each plate, in duplicate
(R2 > 0.997). Absorbance was read using SoftMax Pro software,
which calculated the standard curves and concentrations for each
unknown on a plate by plate basis.
OMERACTeOARSI response criteria
Response to 4Jointz was assessed using amodiﬁed version of the
OMERACTeOARSI set of response criteria19. Participants were
classed as responding if they had high improvement in pain (using
the VAS) or function (using KOOS function scale) of 50% and
absolute change 20; or if they had improvement in both pain and
function of 20% or 10. Criteria for change in participants’ global
assessment were not included as we did not ask questions about
global assessment.
Paracetamol use
Paracetamol usage was recorded at baseline (along with other
medication) and at each subsequent visit. Daily dose was averaged
over a 28-day month in participants who did not use paracetamol
every day.
Muscle strength
Leg strength was measured to the nearest kilogramme in both
legs simultaneously, using a dynamometer (TTM Muscular Meter,
Tokyo, Japan) as previously described21. This tests isometric
strength, predominantly of the quadriceps and hip extensors.
Safety
Adverse events were deﬁned as any untoward event occurring
during the trial regardless of whether it was considered
medication-related. Serious adverse events were deﬁned as
unplanned hospital admissions, new cancer diagnoses (excluding
skin cancer) or death during the 16 weeks of the study. Blood tests
were performed at baseline and 12 weeks to assess safety, and
included general biochemistry, red and white cell parameters and
platelet counts.
Sample size
Sample size for pain intensity using VAS was based on
demonstrating a 10 mm greater reduction compared to placebo
with a standard deviation (SD) of 20 mm22,23. Therefore a change of
10 mm reduction on the VAS (compared to placebo) required 62
participants per group with a ¼ 0.05 and b ¼ 0.20. We aimed to
enrol 70 participants in each group to allow for dropouts.
Randomisation and sequence generation
Participants were randomly allocated to one of two treatment
arms (4Jointz or placebo) using computer generated block ran-
domisation in blocks of four. The random allocation sequence was
automatically generated, and a security protected central auto-
mated allocation procedure was used to allocate participants totreatment arm 1 or 2. This was then used by one author (LL, who
had no contact with participants) to dispense tubes of allocated
medication for the Hobart participants. Research nurses enrolled
participants in the trial, and then gave tubes to each individual
patient. The procedure for Sydney patients was the same except
that the pharmacy at the Royal North Shore Hospital dispensed
allocated medication to Sydney participants. The active treatment
and placebo product were visually and aromatically identical.
Participants and staff involved in patient care remained blinded to
treatment allocation throughout the trial.
Statistical methods
We used Stata 12.0 (StataCorp LP) for statistical analyses.
Statistical signiﬁcance was set as a P value 0.05 (two-tailed).
Adjustments for multiple comparisons were not used. We used
a modiﬁed intent to treat (ITT) approach for data analysis24, where
all patients who were randomised to receive treatment were
included in the analysis. Secondly, missing data was imputed using
Stata’s multiple imputation (MI) functions, using 50 imputations
per observation, from non-missing baseline data, using multivar-
iate normal regression to generate outcome data. Change in
outcomes was assessed using the difference between the factor at
baseline and follow-up, and using linear regression. Data was
checked for normality using Stata’s pnorm and qnorm functions,
and for homogeneity of variance. Since change in CTX-2 and change
in IL-6 both had one highly inﬂuential outlier (>99th percentile),
non-parametric testing was used for the non-imputed analysis
(Somers’ D). Poisson regression was used to compare numbers of
adverse events. Therewas no evidence of overdispersion. Change in
binary outcomes was assessed using logistic regression for panel
data (xtmelogit), clustering on ID to account for correlated
outcomes within an individual.
Post-hoc analyses on the change in outcomes by sex, OARSI
grade and body mass index (BMI) were also performed. Sensitivity
analyses were performed on estimates of the effect of treatment
between baseline and 12 weeks, adjusting for covariates where
there was a statistically or clinically signiﬁcant difference at base-
line (OARSI grade, use of paracetamol, use of glucosamine).
Results
Participants
A total of 167 participants attended screening for the study.
Most participants who were subsequently excluded (n ¼ 34) had
knee OAwhich was too severe (Grade 3 JSN; n¼ 30). The remaining
133 participants were randomised to receive either 4Jointz or
placebo. By 12 weeks 81% of the cohort had been retained, 88% in
the placebo group and fewer patients (75%) in the intervention
group (P ¼ 0.03) (Fig. 1).
Table I shows the characteristics of study participants at baseline
by treatment received. At baseline, participants (n ¼ 133) had
a mean age of 64.8 years, mean BMI of 29.8 and mean VAS score of
53.2. All participants had clinical knee OA, and themajority also had
radiographic OA, deﬁned as any score 1 for JSN or osteophytes17.
Participants receiving 4Jointz and placebo were well matched, but
the groups differed in their use of glucosamine (P ¼ 0.04) and
number of pain medicines (P ¼ 0.049), which were predominantly
differences in use of paracetamol and glucosamine.
Outcomes
For the primary hypotheses of change between baseline and 12
weeks and using the ITT analysis, Table II and Fig. 2 show that the
Fig. 1. Study ﬂow chart.
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in knee pain on the VAS scale and a 5.7 (P ¼ 0.047) point
improvement on the KOOS pain scale, with the effect size of
the estimates remaining similar after adjustment for baseline
differences. Neither change in IL-6 [0.04, 95% CI (0.2e0.07;
P ¼ 0.48)] nor change in cartilage breakdown (0.01, 95% CI 0.1
to þ0.1; P ¼ 0.68) changed signiﬁcantly between baseline and 12
weeks.
For the secondary outcomes, change in pain using the KOOS pain
scale was signiﬁcantly different by 8 weeks, with patients receiving4Jointz experiencing less pain (6.1, P¼ 0.025). Participants receiving
4Jointz also had greater leg strength (2.9 kg, P ¼ 0.02) after 12
weeks of treatment, this result remained statistically signiﬁcant
after adjustment for baseline differences. Treatment with 4Jointz
did not change clinical response (using the OMERACTeOARSI
response criteria), and reductions in paracetamol dose did not
reach statistical signiﬁcance [404.2 mg (95% CI 1268.8e460.4;
P ¼ 0.35)].
Using imputation, the effect size reduced slightly for the pain
outcomes, with signiﬁcance becoming borderline at 12 weeks
Table I
Baseline characteristics of study patients
4Jointz Placebo
n ¼ 64 n ¼ 69
Mean (SD) Mean (SD)
Age 64.3 (9.8) 65.5 (8.3)
Sex (% male) 45 36
Weight 83.3 (15.9) 81.6 (16.6)
BMI 29.7 (4.9) 29.9 (5.1)
Medication use
Paracetamol (%) 30 41
Average paracetamol dose (mg) 1710 (1374.9) 1475 (1165.7)
Fish oil (%) 30 34
Glucosamine (%) 22 38
COX-2 inhibitors (%) 14 16
Radiographic OA (n, %)*
Grade 0 12 (17) 18 (28)
Grade 1 24 (35) 13 (20)
Grade 2 22 21 (16)
Grade 3 0 0
Number of pain medicines (n, %)
0 31 (45) 16 (25)
1 18 (26) 17 (27)
2 7 (10) 16 (25)
3 13 (19) 15 (23)
Previous knee surgery, self-reported (%) 10 14
Pain intensity (VAS score) 52.7 (15.7) 53.8 (14.5)
Pain intensity (KOOS) 57.0 (12.7) 56.2 (15.5)
Symptoms score (KOOS) 59.6 (14.9) 58.6 (16)
IL-6 (pg/mL) 5.7 (7.2) 6.4 (13.9)
CTX-2 (ng/mL) 20.8 (48.4) 21.5 (38.5)
* Radiographic OA is using OARSI criteria.
Fig. 2. Pain intensity (using visual analogue score) over the study time frame, using
unadjusted data and 95% CI of the point estimates. P values are for the effect of
treatment using change in VAS scores from baseline, excepting 16 weeks where P is for
the effect of treatment cessation.
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for KOOS and remained signiﬁcant for muscle strength.
Treatment ceased at 12 weeks. By 16 weeks, pain, symptoms
and leg strength had returned to baseline (Table II).Table II
Effect of treatment with 4Jointz: change in study outcomes between baseline and 4, 8 and
12 and 16 weeks)
4 weeks 8 weeks
Effect size (b coefﬁcient)
(95% CI)
P Effect size (b coefﬁcient
(95% CI)
No imputation n ¼ 124 n ¼ 112
Pain (VAS) 3.0 (10.4e4.4) 0.42 5.7 (13.8e2.3)
Pain (KOOS) 1.3 (3.3e5.9) 0.58 6.1 (0.8e11.4)
Symptoms 1.7 (2.6e6) 0.45 0.2 (5.3e4.9)





1.2 (0.7e2.1) 0.56 1.4 (0.82e2.4)
Paracetamol use (yes/no)* 1.0 (0.6e1.7) 0.85 1.0 (0.8e1.4)
Paracetamol dose (in those
using at baseline)
70.7 (759.9e618.6) 0.84 247.6 (925.6e430.5)
Using imputation n ¼ 133 n ¼ 133
Pain (VAS) 2.5 (10e5.0) 0.52 4.2 (12.4e4)
Pain (KOOS) 1.1 (3.6e5.8) 0.64 5.4 (0.02e10.9)
Symptoms (KOOS) 1.2 (3.3e5.7) 0.59 0.4 (5.5e4.7)
Leg strength (kg) 0.2 (2.2e2.7) 0.85 1.8 (0.9e4.4)
IL-6 e e
CTX-2 e e
OARSIeOMERACT 1.2 (0.6e2.1) 0.63 1.4 (0.8e2.5)
Paracetamol use (yes/no)* 0.4 (0.1e1.5) 0.20 0.4 (0.1e1.6)
Paracetamol dose (in those
using at baseline)
77.5 (685.3e530.2) 0.80 251.7 (834.7e331.3)
The statistics presented are the change in the outcome between baseline and the time p
The number presented is the beta coefﬁcient (and 95% CI) for the additional effect of treatm
Treatment ceased after 12 weeks.
Bold typeface indicates statistically signiﬁcant result (a 0.05).Post-hoc analyses
We conducted some additional post-hoc analyses on the pain
measures. Interactionsbetweentreatment and sexwere signiﬁcantor
almost signiﬁcant using a P value of 0.1. Women responded better to
treatment thanmen, using both the VAS pain intensity score and the
KOOS pain scale; and persons with early OA (OARSI grade 0 or 1)
respondedbetter thanpersonswith lateOA(OARSIgrade2) (Table IV).
Adverse events
Adverse events were common, but the prevalence and number
of adverse events were not different between patients receiving12 weeks of treatment, and change in outcomes after treatment cessation (between
12 weeks Offset effect 12e16 weeks
) P Effect size (b coefﬁcient)
(95% CI)
P Effect size (b coefﬁcient)
(95% CI)
P
n ¼ 106 n ¼ 99
0.16 L9.9 (L19.1 to L0.8) 0.034 9.2 (0.4e17.9) 0.04
0.025 5.7 (0.1e11.3) 0.047 L6.8 (L13.0 to L0.5) 0.03
0.94 4.7 (1.3e10.7) 0.12 L8.5 (L14.1 to L2.8) <0.001
0.13 2.9 (0.5e5.3) 0.02 L2.5 (L4.9 to L0.1) 0.04
0.04 (0.2e0.07) 0.48
0.01 (0.1e0.1) 0.68
0.22 1.3 (0.8e2.2) 0.34 1.1 (0.7e2.0) 0.63
0.82 1.0 (0.8e1.2) 0.80 0.2 (0.02e1.5) 0.11
0.46 404.2 (1268.8e460.4) 0.35 308.9 (802.8e185) 0.21
n ¼ 133 n ¼ 133
0.31 8.7 (17.9e0.5) 0.06 8.1 (1.4e17.7) 0.09
0.049 5.3 (0.7e11.3) 0.08 4.6 (11.8e2.6) 0.20
0.87 3.6 (2.4e9.5) 0.24 L6.3 (L12.5 to L0.03) 0.049
0.19 3.0 (0.2e5.8) 0.035 2.1 (4.6e0.5) 0.11
0.04 (4.4e4.5) 0.99 e
23.3 (90.7e44.2) 0.49 e
0.24 1.3 (1.3e2.2) 0.43 0.8 (1.2 to 0.4) 0.67
0.18 0.4 (0.1e1.6) 0.21 0.81 (0.31e2.1) 0.66
0.39 356.2 (1053.7e341.3) 0.31 222.0 (570.5e126.5) 0.21
oint of interest except the response criteria.
ent over that of placebo except for *odds ratios or yincidence rate ratios, as indicated.
Table III
Prevalence and number of adverse events, by treatment received
Placebo 4Jointz P
n ¼ 62 n ¼ 67
Adverse events
Prevalence of at least one adverse
event (n, %)
38 (61) 48 (72) 0.47
Number of adverse events 67 78 0.85
Prevalence of (n, %) rash 1 (1.6) 14 (21) 0.013
Upper respiratory tract infection 11 (18) 10 (15) 0.69
GI upset 4 (6.5) 2 (3) 0.37
Headache 3 (4.8) 6 (9.1) 0.38
Increased knee pain 3 (4.8) 2 (3) 0.60
Knee swelling 1 (1.6) 1 (1.5) 0.96
Abnormal blood results 24 (41) 29 (44) 0.82
Elective hospital admissions 3 (4.8) 1 (1.5) 0.31
Serious adverse events





Bold typeface indicates statistically signiﬁcant result (a 0.05).
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irritation at the site of application) was signiﬁcantly higher in
patients receiving 4Jointz (risk ratio 13.2, P ¼ 0.013). Participants
experiencing localised irritations were advised to cease using the
treatment, then rechallenge with ointment after a few weeks.
Treatment ceased if the rash recurred. This was severe enough to
discontinue the study drug in four participants (26% of those with
rash) (Fig. 1). One participant had a serious adverse event, which
was a non-elective hospital admission where they received
a cardiac stent, which we considered not causally related to the
study drug.
Discussion
This study demonstrates that 4Jointz is a safe and effective
topical treatment formild tomoderate knee OA in participants aged
50e80 years. 4Jointz was effective in reducing pain at 12 weeks
using both pain measures, and by 8 weeks using the KOOS scale.
4Jointz also increased quadriceps strength by an average of 3 kg
after 12 weeks, but had no effect on systemic inﬂammation or
cartilage breakdown over 12 weeks of treatment. When treatment
was discontinued after 12 weeks, we observed rapid worsening of
pain, symptoms and leg strength. This implies that 4Jointz is
symptom modifying.
This is the longest reported duration of use of comfrey for
osteoarthritic knee pain, with previous trials being of 3 12 or 6
weeks duration16. Patients had the largest responses to treatment
at the last occasion during treatment in this study (12 weeks). All
three trials support a role for comfrey as a topical treatment for
knee pain and OA. However, it is not possible to directly compare
results between our study and these others because the patient
populations are different. The study described in Grube et al.12Table IV
Change in pain scores between baseline and 12 weeks by sex, OARSI grade and BMI, by
Change in: n Placebo
VAS score Females 36 12.9 (21.7 to 4.1)
Males 20 20.4 (31.8 to 8.9)
KOOS pain score Females 35 1.9 (2.8e6.6)
Males 19 11.0 (6.0e16)
VAS score Early OA* 29 9.9 (20.3e0.5)
Late OA 17 22.3 (33.7 to 10.9)
Bold typeface indicates statistically signiﬁcant result (a 0.05).
* Early OA is OARSI grade 0 or 1, late OA is OARSI grade 2.included participants with knee pain but not necessarily knee OA,
and with pain scores (on VAS) as low as 23 mm suggesting that
participants in the Grube trial may not have knee OA, or are earlier
in the disease course. The larger effect observed in this study is
consistent with our results in early OA. They also requested
participants discontinue other medication. Omitting participants
taking analgesics or anti-inﬂammatory medications would rule out
nearly 60% of our participants and thus our results should be seen
as an additional beneﬁt with 4Jointz rather than the sole beneﬁt.
Grube et al.12 also observed a much greater reduction in pain with
the use of comfrey thanwe did at a comparable time point, but this
may be due to the use of an aggregate of two WOMAC subscales,
artefactually doubling the apparent magnitude of beneﬁt.
While our results show that 4Jointz is superior to placebo, we
observed clinically important changes in self rated outcomes in
both treatment groups. These were most evident with pain but we
also observed them in the KOOS symptom score.
The skin irritation appears causally related to the use of 4Jointz.
Otherwise, the side effect proﬁle we observed is similar to reported
in a pilot study of 4Jointz12,16. Only the study by Smith et al. 16 re-
ported the rash. Overall 4Jointz appears safe and well tolerated.
Most importantly, the renal toxicity associated with pyrrolizidine-
type alkaloids, associated with oral use of comfrey25 appears
absent in topical use, as expected, with no change in systemic blood
tests. The skin irritation reversed on cessation of treatment, and
only reappeared in around one-quarter of those with rash.
We supplied participants with one tube of cream per month.We
have observed clinically signiﬁcant changes with one tube of cream
per month or about 3.5 g/day. Since only one dose of 4Jointz was
used in this study we cannot compare with other concentrations.
However, Smith et al. compared formulations of, 10% and 20%
comfrey extract and pseudoplacebo, and whilst both were superior
to placebo, the treatment armswere not signiﬁcantly different from
each other16.
Since post-hoc analyses suggested that treatment may be most
effective in women and those with milder radiographic OA, future
studies should consider studies speciﬁcally in these populations.
Strengths of this study include the comparatively long duration
of treatment, the deﬁned study population and standardised
meaningful outcomemeasures. Themajor limitation of this study is
the difference in dropout rates between the groups receiving
placebo and 4Jointz, with more patients ceasing treatment in the
4Jointz group. This included but was not limited to patients who
experienced rash and were advised to cease treatment. However,
we have imputed missing data and the results are similar but of
slightly lower magnitude to those obtained in the main analysis,
giving us conﬁdence that our results have not been substantially
inﬂuenced by unequal dropouts between groups.Conclusions
Topical treatment using 4Jointz is a safe and effective treatment
for the symptoms of knee OA in participants with moderate kneetreatment group
n 4Jointz Diff. P
24 29.7 (37.1 to 22.2) 16.8 0.008
26 21.6 (31.4 to 11.7) 1.2 0.87
23 10.6 (5.2e16.0) 8.7 0.018
26 10.9 (3.8e18.1) 0.1 0.99
26 26 0 (31.6 to 20.4) 16.1 0.009
16 29.6 (42 to 17.3) 7.3 0.36
L.L. Laslett et al. / Osteoarthritis and Cartilage 20 (2012) 1209e1216 1215pain on most days, and clinical OA. In particular, it reduces
pain and increases muscle strength, but has no effect on
systemic inﬂammation or cartilage breakdown over 12 weeks of
treatment.
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